AU
UK
CA
US
IND
NZ
Last update at 2025-11-06T20:10:50.352480Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Wed 14 May 25, 08:01 PM7 Short-Squeeze Stocks That Could Beat Down the Bears
Mon 15 Jul 24, 12:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -36.83800M | -28.03400M | -32.20900M | -32.99600M | -29.44300M |
| Minority interest | - | - | - | - | - |
| Net income | -37.51900M | -30.48600M | -34.39300M | -34.41500M | -29.44300M |
| Selling general administrative | 20.62M | 9.78M | 11.78M | 8.27M | 13.72M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | 0.00000M |
| Reconciled depreciation | 0.47M | 0.44M | 0.40M | 0.36M | 0.33M |
| Ebit | -36.15700M | -25.82300M | -29.93300M | -32.90500M | -28.34300M |
| Ebitda | -33.53600M | -25.45900M | -29.62200M | -31.22900M | -28.01100M |
| Depreciation and amortization | 2.62M | 0.36M | 0.31M | 1.68M | 0.33M |
| Non operating income net other | 2.62M | 0.36M | 0.31M | 1.68M | 1.66M |
| Operating income | -36.15700M | -25.82300M | -29.93300M | -32.90500M | -29.66700M |
| Other operating expenses | 36.16M | 25.82M | 29.93M | 32.91M | 29.67M |
| Interest expense | 3.30M | 2.58M | 2.59M | 1.77M | 1.43M |
| Tax provision | - | - | - | - | - |
| Interest income | 1.20M | 0.05M | 0.32M | 1.66M | 1.71M |
| Net interest income | -2.09900M | -2.52600M | -2.27200M | -0.10700M | 0.28M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.68M | 2.45M | 2.18M | 1.42M | -0.22400M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 36.16M | 25.82M | 29.93M | 32.91M | 29.67M |
| Cost of revenue | - | - | - | - | 0.00000M |
| Total other income expense net | -0.68100M | -2.21100M | -2.27600M | -0.09100M | -0.05600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -36.83800M | -28.03400M | -32.20900M | -32.99600M | -29.44300M |
| Net income applicable to common shares | -36.83800M | -28.03400M | -32.20900M | -32.99600M | -29.44300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 94.48M | 124.19M | 79.04M | 109.05M | 77.28M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.60M | 1.43M | 0.02M | 0.12M | 0.09M |
| Total liab | 57.26M | 51.76M | 22.57M | 26.88M | 25.92M |
| Total stockholder equity | 37.22M | -226.53600M | -189.69800M | -161.66400M | -129.45500M |
| Deferred long term liab | - | 7.52M | - | - | 0.77M |
| Other current liab | 8.96M | 5.33M | 0.03M | 4.79M | 3.69M |
| Common stock | 0.00400M | 0.00300M | 0.00300M | 0.00300M | 0.00200M |
| Capital stock | 0.00400M | 0.00300M | 0.00300M | 0.00300M | 0.00200M |
| Retained earnings | -281.34600M | -226.53600M | -189.69800M | -161.66400M | -129.45500M |
| Other liab | - | 7.54M | 0.37M | 0.22M | 0.06M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.27M | 0.28M | 1.13M | 0.33M |
| Cash | 46.81M | 71.06M | 74.27M | 105.28M | 72.81M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 13.13M | 7.42M | 14.85M | 9.32M | 5.24M |
| Current deferred revenue | - | - | 4.00M | - | - |
| Net debt | -6.54500M | -33.69300M | -56.63300M | -85.07100M | -52.54100M |
| Short term debt | 0.18M | 0.57M | 10.28M | 2.87M | 0.41M |
| Short long term debt | - | - | 9.80M | 2.41M | - |
| Short long term debt total | 40.27M | 37.37M | 17.64M | 20.21M | 20.27M |
| Other stockholder equity | 318.56M | -0.03500M | -0.00200M | -0.00400M | -0.00200M |
| Property plant equipment | - | 0.05M | 0.07M | 0.91M | 1.31M |
| Total current assets | 92.94M | 123.31M | 78.28M | 107.83M | 75.65M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 72.43M | 63.11M | 82.17M | 51.37M |
| Short term investments | 29.20M | 47.12M | 1.01M | 33.28M | - |
| Net receivables | 4.49M | 2.28M | - | - | 0.31M |
| Long term debt | 38.81M | 36.79M | 7.35M | 16.86M | 18.91M |
| Inventory | 8.84M | 1.23M | - | - | 2.44M |
| Accounts payable | 4.00M | 1.52M | 0.54M | 1.67M | 1.14M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.00100M | 0.03M | -0.00100M | 0.00100M | -0.10200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00300M | 0.00300M | 0.00300M | 0.00200M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -226.53600M | -189.69800M | -161.66400M | -129.45500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.08M | 0.27M | 0.28M | 0.31M | 0.33M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.54M | 0.89M | 0.76M | 1.22M | 1.64M |
| Capital lease obligations | 1.46M | 0.57M | 0.48M | 0.94M | 1.35M |
| Long term debt total | - | 36.79M | 7.35M | 16.86M | 18.91M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -45.83800M | 32.14M | -33.46000M | -33.46000M | -33.46000M |
| Change to liabilities | 1.77M | -2.36500M | 1.21M | 0.96M | -1.37700M |
| Total cashflows from investing activities | -45.85900M | 32.13M | -33.46000M | -33.46000M | -33.46000M |
| Net borrowings | 29.80M | -2.50000M | -2.50000M | 9.55M | -0.06200M |
| Total cash from financing activities | 77.23M | -2.53000M | 60.35M | 13.59M | -0.00800M |
| Change to operating activities | -0.88700M | -0.23400M | 0.24M | -0.61100M | -0.83300M |
| Net income | -36.83800M | -28.03400M | -32.20900M | -32.99600M | -29.44300M |
| Change in cash | -3.20700M | 2.45M | -0.80500M | -16.85400M | -28.82000M |
| Begin period cash flow | 74.45M | 72.00M | 72.81M | 89.66M | 118.48M |
| End period cash flow | 71.24M | 74.45M | 72.00M | 72.81M | 89.66M |
| Total cash from operating activities | -34.57700M | -27.15100M | -27.69300M | -30.44200M | -28.81200M |
| Issuance of capital stock | 47.77M | 0.00000M | 60.58M | 3.97M | 0.00000M |
| Depreciation | 0.47M | 0.44M | 0.40M | 0.36M | 0.33M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -1.23000M | -1.23000M | -1.23000M | -1.23000M | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | 1.34M | -0.08100M | -0.16400M | 4.03M | -0.00400M |
| Other cashflows from financing activities | 46.96M | 0.05M | -0.06400M | 9.62M | 0.06M |
| Change to netincome | 3.72M | 2.92M | 2.67M | 1.83M | 2.51M |
| Capital expenditures | 0.02M | 0.00900M | 0.00900M | 0.00900M | 0.00900M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | -1.79100M | -0.23400M | 0.27M | -0.60900M | -0.83300M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -3.20700M | 2.45M | -0.80500M | -16.85400M | -28.82000M |
| Change in working capital | -0.35000M | -2.59900M | 1.45M | 0.35M | -2.21000M |
| Stock based compensation | 2.84M | 2.37M | 2.00M | 1.45M | 2.13M |
| Other non cash items | -0.69500M | 0.68M | 0.64M | 0.39M | 0.37M |
| Free cash flow | -34.59800M | -27.16000M | -27.69300M | -30.44200M | -28.81200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SCPH Scpharmaceuticals Inc |
- -% | - | - | - | 13.08 | 4.78 | 10.45 | -3.083 |
| NVO Novo Nordisk A/S |
1.75 4.17% | 43.75 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.78 4.22% | 44.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
13.40 3.13% | 441.74 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
9.78 1.58% | 628.73 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
25 Mall Road, Burlington, MA, United States, 01803
| Name | Title | Year Born |
|---|---|---|
| Mr. John H. Tucker | Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director | 1963 |
| Ms. Rachael Nokes | Sr. VP of Fin. & Principal Accounting Officer | 1975 |
| Katherine Taudvin | Director of Corp. Devel. & Investor Relations | NA |
| Dr. John Mohr Pharm.D. | Sr. VP of Clinical Devel. & Medical Affairs | NA |
| Mr. Michael D. Hassman | Sr. VP of Technical Operations | NA |
| Mr. John H. Tucker | President, CEO, Principal Executive Officer & Director | 1963 |
| Ms. Rachael Nokes | CFO & Principal Accounting Officer | 1976 |
| Mr. Michael D. Hassman | Senior Vice President of Technical Operations | NA |
| Katherine Taudvin | Vice President of Corporate Affairs & Human Resources | NA |
| Dr. John Mohr Pharm.D. | Senior Vice President of Clinical Development & Medical Affairs | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...